Dipòsit Digital de Documents de la UAB 17 registres trobats  1 - 10següent  anar al registre: La cerca s'ha fet en 0.01 segons. 
1.
1 p, 257.6 KB Publisher Correction : Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study / Kayser, Sabine (Heidelberg University Hospital (Alemanya)) ; Rahmé, Ramy (Université Paris Diderot. Hôpital Saint Louis) ; Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ; Ghiaur, Gabriel (Johns Hopkins University) ; Thomas, Xavier (Centre Hospitalier Lyon-Sud) ; Guerci-Bresler, Agnes (Nancy University Hospital) ; Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Pigneux, Arnaud (Bordeaux University Hospital) ; Gil, Cristina (Hospital General, Alicante) ; Raffoux, Emmanuel (Université Paris Diderot) ; Tormo, Mar (Universitat de València) ; Vey, Norbert (Institut Paoli Calmette) ; de la Serna, Javier (Hospital 12 de Octubre (Madrid)) ; Salamero, Olga (Hospital Universitari Vall d'Hebron) ; Lengfelder, Eva (University Hospital Mannheim) ; Levis, Mark (Johns Hopkins University) ; Fenaux, Pierre (Université Paris Diderot) ; Sanz, Miguel A. (Centro de Investigación Biomédica en Red de Cáncer) ; Platzbecker, Uwe (University Hospital Leipzig. Medical Clinic and Policlinic I, Hematology and Cellular Therapy) ; Schlenk, Richard F. (NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital) ; Adès, Lionel (Université Paris Diderot) ; Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ; Universitat Autònoma de Barcelona
2021 - 10.1038/s41375-021-01358-3
Leukemia, Vol. 35 (november 2021) , p. 3631  
2.
1.2 MB Molecular landscape and prognostic impact of FLT3 -ITD insertion site in acute myeloid leukemia : RATIFY study results / Rücker, Frank G. (Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany) ; Du, Ling (Novartis Pharmaceuticals, Cambridge) ; Luck, Tamara J. (Charité University, Berlin) ; Benner, Axel (German Cancer Research Center, Heidelberg) ; Krzykalla, Julia (German Cancer Research Center, Heidelberg) ; Gathmann, Insa (Novartis Pharmaceuticals, Basel) ; Voso, Maria Teresa (Università di Roma "Tor Vergata", Rome) ; Amadori, Sergio (Università di Roma "Tor Vergata", Rome) ; Prior, Thomas W. (The Ohio State University Comprehensive Cancer Center, Columbus) ; Brandwein, Joseph M. (University of Alberta, Edmonton) ; Appelbaum, Frederick R. (Fred Hutchinson Cancer Research Center, Seattle) ; Medeiros, Bruno (Stanford University) ; Tallman, Martin S. (Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York) ; Savoie, Lynn (University of Calgary, Calgary) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Pallaud, Celine (Novartis Pharmaceuticals, Basel) ; Sanz, Miguel A. (Hospital Universitari i Politècnic La Fe, València) ; Jansen, Joop H. (Radboud University Medical Center, Nijmegen) ; Niederwieser, Dietger (Hematology and Oncology, University of Leipzig, Leipzig) ; Fischer, Thomas (Otto-von-Guericke University Magdeburg, Magdeburg) ; Ehninger, Gerhard (Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden) ; Heuser, Michael (Hannover Medical School, Hannover) ; Ganser, Arnold (Oncology and Stem Cell Transplantation, Hannover) ; Bullinger, Lars (Charité University, Berlin) ; Larson, Richard A. (University of Chicago, Chicago) ; Bloomfield, Clara D. (The Ohio State University Comprehensive Cancer Center, Columbus) ; Stone, Richard M. (Dana-Farber/Partners CancerCare, Boston) ; Döhner, Hartmut (University Hospital of Ulm) ; Thiede, Christian (Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden) ; Döhner, Konstanze (University Hospital of Ulm) ; Universitat Autònoma de Barcelona
In acute myeloid leukemia (AML) internal tandem duplications of the FLT3 gene (FLT3- ITD) are associated with poor prognosis. Retrospectively, we investigated the prognostic and predictive impact of FLT3 -ITD insertion site (IS) in 452 patients randomized within the RATIFY trial, which evaluated midostaurin additionally to intensive chemotherapy. [...]
2021 - 10.1038/s41375-021-01323-0
Leukemia, Vol. 36 (july 2021) , p. 90-99  
3.
9 p, 621.5 KB Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study / Kayser, Sabine (Heidelberg University Hospital. Department of Internal Medicine V) ; Rahmé, Ramy (Université Paris Diderot) ; Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ; Ghiaur, Gabriel (Johns Hopkins University) ; Thomas, Xavier (Centre Hospitalier Lyon-Sud. Hospices Civils de Lyon) ; Sobas, Marta (Wroclaw Medical University) ; Guerci-Bresler, Agnes (Nancy University Hospital) ; Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Pigneux, Arnaud (Bordeaux University Hospital) ; Gil, Cristina (Hospital General, Alicante, Spain) ; Raffoux, Emmanuel (Université Paris Diderot. Hôpital Saint Louis) ; Tormo, Mar (Hospital Clínic Universitari (València)) ; Vey, Norbert (Institut Paoli Calmette) ; de la Serna, Javier (Hospital 12 de Octubre (Madrid)) ; Salamero, Olga (Hospital Universitari Vall d'Hebron) ; Lengfelder, Eva (University Hospital Mannheim. Department of Hematology and Oncology) ; Levis, Mark (Johns Hopkins University) ; Fenaux, Pierre (Université Paris Diderot. Hôpital Saint Louis) ; Sanz, Miguel A. (Centro de Investigación Biomédica en Red de Cáncer) ; Platzbecker, Uwe (University Hospital Leipzig) ; Schlenk, Richard F. (German Cancer Research Center and Heidelberg University Hospital) ; Adès, Lionel (Université Paris Diderot) ; Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ; Universitat Autònoma de Barcelona
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73. [...]
2020 - 10.1038/s41375-020-0758-4
Leukemia, Vol. 34 (february 2020) , p. 2333-2341  
4.
10 p, 1.8 MB Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma : Updated Overall Survival, Safety, and Subgroups / Orlowski, R.Z. (Department of Lymphoma and Myeloma. The University of Texas M.D. Anderson Cancer Center) ; Moreau, P. (Department of Hematology. University Hospital Hotel-Dieu) ; Niesvizky, R. (Department of Medical Oncology. Myeloma Center. New York Presbyterian Hospital-Weill Cornell Medical Center) ; Ludwig, H. (Wilhelminen Cancer Research Institute (Viena, Àustria)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Chng, W.J. (Department of Hematology Oncology. National University of Singapore) ; Goldschmidt, H. (Department of Hematology Oncology. Heidelberg University Clinic and the National Center of Tumor Diseases) ; Yang, Z. (Department of Biostatistics. Amgen. Inc) ; Kimball, A.S. (Department of Clinical Research. Amgen. Inc) ; Dimopoulos, M. (Department of Clinical Therapeutics. University Athens School of Medicine) ; Universitat Autònoma de Barcelona
Introduction: The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple Myeloma (ENDEAVOR) trial showed significantly improved progression-free survival and overall survival (OS) with carfilzomib (56 mg/m) and dexamethasone (Kd56) versus bortezomib and Kd56 (Vd) in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2019 - 10.1016/j.clml.2019.04.018
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 8 (august 2019) , p. 522-530.e1  
5.
36 p, 6.5 MB CD133-directed CAR T-cells for MLL leukemia : on-target, off-tumor myeloablative toxicity / Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zanetti, SR (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Baroni, Matteo Libero. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sánchez-Martínez, D. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Closa, A. (Universitat Pompeu Fabra) ; Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Marín, P. (Hospital Clínic i Provincial de Barcelona) ; Eyras, E. (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Varela, I. (Instituto de Biomedicina y Biotecnología de Cantabria (CSIC-UC-Sodercan). Departamento de Biología Molecular. Universidad de Cantabria) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2019 - 10.1038/s41375-019-0418-8
Leukemia, Vol. 33 Núm. 8 (january 2019) , p. 2090-2125  
6.
13 p, 3.4 MB NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia / López-Millán, Belén (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sanchéz-Martínez, Diego (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Díaz de la Guardia, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster, J.L. (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ; Ballerini, P. (Pediatric Hematology. Armand Trousseau Hospital) ; Suessbier, U. (Hematology Department. University Hospital-University of Zurich) ; Nombela-Arrieta, C. (Hematology Department. University Hospital-University of Zurich) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. [...]
2019 - 10.1038/s41375-018-0353-0
Leukemia, Vol. 33 Núm. 7 (january 2019) , p. 1557-1569  
7.
12 p, 1.8 MB Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies / Leleu, X. (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ; Beksac, M. (Department of Hematology. Ankara University) ; Chou, T. (Niigata Cancer Center Hospital) ; Dimopoulos, M. (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ; Yoon, S.S. (Department of Internal Medicine. Seoul National University) ; Prince, H.M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Pour, L. (Department of Internal Medicine. Hematology and Oncology. University Hospital Brno) ; Shelekhova, T. (Clinic of Professional Pathology) ; Chari, A. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica). Tisch Cancer Institute) ; Khurana, M. (Clinical Development. Oncology. Amgen Inc) ; Zhang, J. (Global Biostatistical Science. Amgen Inc) ; Obreja, M. (Global Biostatistical Science. Amgen Inc) ; Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ; Universitat Autònoma de Barcelona
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). [...]
2020 - 10.1080/10428194.2020.1832672
Leukemia and Lymphoma, 2020  
8.
15 p, 3.4 MB Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS / Kuendgen, A. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tuechler, H. (Boltzmann Institute for Leukemia Research. Hanusch Hospital) ; Garcia-Manero, G. (Department of Leukemia. MD Anderson Cancer Center) ; Komrokji, R.S. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ; Sekeres, M.A. (Leukemia Program. Department of Hematology and Medical Oncology. Taussig Cancer Institute. Cleveland Clinic) ; Della Porta, M.G. (Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University) ; Cazzola, M. (Department of Hematology Oncology. IRCCS Policlinico San Matteo Foundation) ; DeZern, A.E. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University) ; Roboz, G.J. (Weill Cornell Medicine and The New York Presbyterian Hospital) ; Steensma, D.P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Van de Loosdrecht, A.A. (Vrije Universiteit Amsterdam) ; Schlenk, R.F. (Department of Internal Medicine V. Heidelberg University Hospital) ; Grau, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Blum, S. (Service of Hematology. University Hospital Lausanne) ; Pereira, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Valent, P. (Department of Internal Medicine I. Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology. Medical University of Vienna) ; Costa, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Giagounidis, A. (Department of Oncology. Hematology and Palliative Care. Marienhospital Duesseldorf) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Döhner, H. (Department of Internal Medicine III. University Hospital Ulm) ; Platzbecker, U. (University Hospital Leipzig) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Lübbert, M. (Department of Hematology. Oncology and Stem Cell Transplantation. University Medical Center Freiburg. Faculty of Medicine) ; Oiartzabal, I. (Clinical Hematology Department. Hospital Universitario Araba) ; Díez-Campelo, M. (Clinical Hematology Department. Hospital Universitario de Salamanca (HUSA)) ; Cedena, M.T. (Hospital Universitario 12 de Octubre (Madrid)) ; Machherndl-Spandl, S. (1st. Internal Department - Hematology with stem cell transplants. Hemostaseology and Medical Oncology. Elisabethinen Hospital) ; López-Pavía, M. (Clinical Hematology Department. Hospital General Universitari de València) ; Baldus, C.D. (Department of Hematology and Oncology. University Hospital Schleswig-Holstein. Campus Kiel) ; Martinez-de-Sola, M. (Parc Taulí Hospital Universitari) ; Stauder, R. (Department of Internal Medicine V (Hematology and Oncology). Innsbruck Medical University) ; Merchan, B. (Hospital Universitari Vall d'Hebron) ; List, A. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ; Ganster, C. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ; Schroeder, T. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Voso, Maria Teresa (Department of Biomedicine and Prevention. Tor Vergata University) ; Pfeilstöcker, M. (Hanusch Krankenhaus Wien) ; Sill, H. (Medizinische Universität Graz) ; Hildebrandt, B. (Institute of Human Genetics. University Duesseldorf) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Nomdedeu, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cobo, F. (Clinical Hematology Department. Hospital Quirón Teknon) ; Haas, R. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Germing, U. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Greenberg, P.L. (Stanford University Cancer Center) ; Haase, D. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ; Sanz, G. (Hospital Universitari i Politècnic La Fe de Valencia) ; Universitat Autònoma de Barcelona
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. [...]
2020 - 10.1038/s41375-020-0917-7
Leukemia, 2020  
9.
5 p, 786.3 KB B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation / Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Piñeyro, David (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Javierre, BM (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Raurell Vila, Helena (Institut Germans Trias i Pujol) ; Subirana-Granés, Marc (Institut Germans Trias i Pujol) ; Pasquali, Lorenzo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martinez-Climent, J.A. (Centro de Investigación Biomédica en Red de Cáncer) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2020 - 10.1038/s41375-019-0643-1
Leukemia, Vol. 34 Núm. 4 (april 2020) , p. 1158-1162  
10.
11 p, 1.4 MB Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials / Weisel, K. (Department of Hematology. Oncology. Immunology. Rheumatology. and Pulmonology. Medical Clinic II) ; Majer, I. (Amgen Europe GmbH) ; DeCosta, L. (Amgen Ltd) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Goldschmidt, H. (Internal Medicine V and National Center of Tumor Diseases. University Clinic Heidelberg) ; Ludwig, H. (Wilhelminen Cancer Research Institute. Wilhelminenspital) ; Campioni, M. (Amgen Europe GmbH) ; Szabo, Z. (Amgen Europe GmbH) ; Dimopoulos, M. (School of Medicine. National and Kapodistrian University of Athens. Alexandra Hospital) ; Universitat Autònoma de Barcelona
In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. [...]
2020 - 10.1080/10428194.2019.1648806
Leukemia and Lymphoma, Vol. 61 Núm. 1 (february 2020) , p. 37-46  

Dipòsit Digital de Documents de la UAB : 17 registres trobats   1 - 10següent  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.